Effect of diabetes and aminoguanidine therapy on renal advanced glycation end-product binding
- 1 March 1999
- journal article
- Published by Elsevier in Kidney International
- Vol. 55 (3), 907-916
- https://doi.org/10.1046/j.1523-1755.1999.055003907.x
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Molecular identity and cellular distribution of advanced glycation endproduct receptors: relationship of p60 to OST-48 and p90 to 80K-H membrane proteins.Proceedings of the National Academy of Sciences, 1996
- Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatmentKidney International, 1996
- Advanced glycosylation end products in diabetic renal and vascular diseaseAmerican Journal of Kidney Diseases, 1995
- Antibacterial activity of lysozyme and lactoferrin is inhibited by binding of advanced glycation–modified proteins to a conserved motifNature Medicine, 1995
- Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins.Proceedings of the National Academy of Sciences, 1994
- Glycation and Diabetic ComplicationsDiabetes, 1994
- Mechanism of Inhibition of Advanced Glycosylation by Aminoguanidine in VitroJournal of Carbohydrate Chemistry, 1993
- Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications.Proceedings of the National Academy of Sciences, 1992
- Hemoglobin-AGE: A Circulating Marker of Advanced GlycosylationScience, 1992
- Retardation by Aminoguanidine of Development of Albuminuria, Mesangial Expansion, and Tissue Fluorescence in Streptozocin-Induced Diabetic RatDiabetes, 1991